^
18d
MANTRA: Multimodal Anesthesia in Robotic Laparoscopic Nephrectomy (clinicaltrials.gov)
P=N/A, N=80, Recruiting, Fundacio Puigvert | Not yet recruiting --> Recruiting
Enrollment open
|
dexamethasone injection • ondansetron intravenous
18d
Individualizing Corticosteroid Use in Pneumonia (clinicaltrials.gov)
P2, N=24, Completed, Mayo Clinic | Recruiting --> Completed | Trial completion date: Dec 2026 --> Apr 2026 | Trial primary completion date: Dec 2026 --> Apr 2026
Trial completion • Trial completion date • Trial primary completion date
|
dexamethasone
18d
CAC-PPCL-001: A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia (clinicaltrials.gov)
P2, N=20, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Active, not recruiting
Enrollment closed
|
lenalidomide • bortezomib • dexamethasone
18d
Enrollment open
|
dexamethasone injection
18d
Dexamethasone Palmitate for PONV After Minimally Invasive Endoscopic Surgery (clinicaltrials.gov)
P=N/A, N=588, Completed, Beijing Tiantan Hospital | Recruiting --> Completed | Trial completion date: Dec 2026 --> May 2026 | Trial primary completion date: Nov 2026 --> Apr 2026
Trial completion • Trial completion date • Trial primary completion date
|
dexamethasone injection
19d
New trial
|
dexamethasone injection
19d
AdeCroS: Adelmidrol in Chronic Sinusitis (clinicaltrials.gov)
P=N/A, N=60, Completed, University of Campania Luigi Vanvitelli
New trial
19d
FPNS-IWD: Efficacy and Safety of Fluticasone Propionate Nebulized Suspension for Wheezing Diseases in Infants Aged 0-24 Months (clinicaltrials.gov)
P4, N=240, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
New P4 trial
20d
New trial
|
dexamethasone
23d
Case Report: Longitudinal analysis of local immunoregulatory mediators in a DLBCL vitreoretinal lymphoma receiving local chemotherapy. (PubMed, Front Med (Lausanne))
A patient in their 70s with unilateral VRL underwent nine serial vitreous samplings over 12 weeks of IVT therapy with methotrexate (460 μg/injection) and dexamethasone (0.4 mg/injection)...These findings propose a novel framework for integrating intraocular immunomonitoring into personalized therapeutic strategies and deepen our understanding of the complex tumor-immune microenvironment in vitreoretinal lymphoma. As derived from a single case, these observations are hypothesis-generating and require confirmation in larger cohorts.
Journal
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • HGF (Hepatocyte growth factor) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • IL10 (Interleukin 10) • CCL4 (Chemokine (C-C motif) ligand 4) • FGF2 (Fibroblast Growth Factor 2) • IL17A (Interleukin 17A) • IL1R1 (Interleukin 1 receptor, type I) • IL16 (Interleukin 16)
|
dexamethasone injection
23d
Enrollment open
|
methylprednisolone sodium succinate